FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy
December 19, 2025, 3:36 am
FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumors resistant to current therapies. A crucial Phase 1 trial is underway in the United States. Initial clinical data is expected by mid-2026. This investment accelerates a new era in precision oncology. It offers hope for difficult-to-treat solid tumors.
FoRx Therapeutics, a Swiss-based biotech, recently finalized a significant Series A funding round. The company raised €42 million, equivalent to $50 million. This capital injection propels its innovative anti-cancer drug development. FoRx focuses on precision therapeutics. Their flagship candidate is FORX-428. This compound represents a next-generation approach to cancer treatment. It targets the DNA Damage Response (DDR) pathway. The goal is to address treatment-resistant cancers. This financing underscores strong investor belief in FoRx's pipeline.
Cancer cells often exploit DNA repair mechanisms. The DNA Damage Response (DDR) pathway is crucial. Scientists discovered that specific cancer types are vulnerable to DDR interference. This led to the development of PARP inhibitors. These drugs transformed cancer treatment over a decade ago. They block a key DNA repair enzyme. However, many cancers develop resistance to PARP inhibitors. A new strategy is urgently needed for these patients.
FoRx Therapeutics pursues such a strategy. The company targets PARG (poly (ADP-ribose) glycohydrolase). PARG is another vital DNA repair enzyme. It plays a role in the survival of genetically defined cancers. These cancers often exhibit specific DDR deficiencies. They also show high replication stress. FORX-428 is FoRx's proprietary PARG inhibitor. It is an orally available small molecule. FORX-428 disrupts PARG function. This novel mechanism promises to overcome PARP inhibitor resistance. It offers a new therapeutic avenue.
Preclinical studies of FORX-428 showed impressive results. The compound demonstrated robust anti-tumor activity. This efficacy was observed across multiple solid tumor types. FORX-428 exhibited potential both as a monotherapy. It also showed promise in combination settings. These findings highlight its outstanding therapeutic potential. The drug was well tolerated in these studies. It showed favorable safety and drug-like pharmacology.
Clinical development of FORX-428 is now advancing. A first-in-human Phase 1 study is underway. Recruitment began in August 2025. The study is being conducted in the United States. It is an open-label trial. The primary objectives include evaluating safety and tolerability. Researchers are also assessing pharmacokinetics. Preliminary efficacy will also be monitored. Patients with advanced solid tumors are participating. These individuals have exhausted standard-of-care options. Initial clinical data is keenly anticipated. Readout is expected by mid-2026.
Existing investors led this latest funding round. EQT Life Sciences, Pfizer Ventures, and Novartis Venture Fund participated. M Ventures also contributed significantly. These same investors provided earlier funding. That capital supported the Investigational New Drug (IND) application. It also facilitated the initiation of the Phase 1 trial. This continued support reflects deep confidence. It signals belief in FoRx's lead candidate, FORX-428. It also validates the management team's progress. The company expressed gratitude for securing this syndicate's continued trust. The investment empowers critical clinical milestones.
FoRx's financing mirrors a broader trend. European biotech investment remains robust. Capital flows into novel cancer mechanisms. Other companies also secured substantial funding in 2025. Hedera Dx, another Swiss firm, raised €15 million. This expanded access to targeted cancer care. Highlight Therapeutics in Spain received €15 million. They advance immuno-oncology treatments. T-Therapeutics in the UK secured €27.5 million. They develop immune-based therapies. Larger, later-stage rounds also occurred. Adcytherix in France closed €105 million. This financed antibody-drug conjugates. Artios Pharma raised €99 million. This expanded its precision oncology pipeline.
Collectively, these disclosed rounds total roughly €306 million in 2025. This funding focuses on European oncology biotechs. FoRx's investment aligns with this pattern. It shows sustained interest in differentiated cancer biology. Targets range from DNA damage response pathways to immuno-oncology. Targeted delivery platforms also attract capital. This widespread investment highlights a dynamic sector. Innovation in cancer treatment continues at pace.
The potential impact of PARG inhibition is significant. It represents a promising therapeutic strategy in oncology. FoRx aims to reinforce FORX-428's best-in-class profile. The company seeks to make a substantial difference for patients. Those with resistant cancers often face limited options. FORX-428 could offer renewed hope. It targets a critical vulnerability in these tumors. The upcoming clinical data will be pivotal. It will inform future development pathways.
FoRx Therapeutics stands at a critical juncture. Its new funding accelerates a novel cancer therapy. FORX-428 holds immense promise. It offers a new weapon against advanced solid tumors. The biotech sector watches closely. Patients worldwide await breakthroughs. This investment drives progress. It moves science closer to a cure for resistant cancers.
FoRx Therapeutics, a Swiss-based biotech, recently finalized a significant Series A funding round. The company raised €42 million, equivalent to $50 million. This capital injection propels its innovative anti-cancer drug development. FoRx focuses on precision therapeutics. Their flagship candidate is FORX-428. This compound represents a next-generation approach to cancer treatment. It targets the DNA Damage Response (DDR) pathway. The goal is to address treatment-resistant cancers. This financing underscores strong investor belief in FoRx's pipeline.
Cancer cells often exploit DNA repair mechanisms. The DNA Damage Response (DDR) pathway is crucial. Scientists discovered that specific cancer types are vulnerable to DDR interference. This led to the development of PARP inhibitors. These drugs transformed cancer treatment over a decade ago. They block a key DNA repair enzyme. However, many cancers develop resistance to PARP inhibitors. A new strategy is urgently needed for these patients.
FoRx Therapeutics pursues such a strategy. The company targets PARG (poly (ADP-ribose) glycohydrolase). PARG is another vital DNA repair enzyme. It plays a role in the survival of genetically defined cancers. These cancers often exhibit specific DDR deficiencies. They also show high replication stress. FORX-428 is FoRx's proprietary PARG inhibitor. It is an orally available small molecule. FORX-428 disrupts PARG function. This novel mechanism promises to overcome PARP inhibitor resistance. It offers a new therapeutic avenue.
Preclinical studies of FORX-428 showed impressive results. The compound demonstrated robust anti-tumor activity. This efficacy was observed across multiple solid tumor types. FORX-428 exhibited potential both as a monotherapy. It also showed promise in combination settings. These findings highlight its outstanding therapeutic potential. The drug was well tolerated in these studies. It showed favorable safety and drug-like pharmacology.
Clinical development of FORX-428 is now advancing. A first-in-human Phase 1 study is underway. Recruitment began in August 2025. The study is being conducted in the United States. It is an open-label trial. The primary objectives include evaluating safety and tolerability. Researchers are also assessing pharmacokinetics. Preliminary efficacy will also be monitored. Patients with advanced solid tumors are participating. These individuals have exhausted standard-of-care options. Initial clinical data is keenly anticipated. Readout is expected by mid-2026.
Existing investors led this latest funding round. EQT Life Sciences, Pfizer Ventures, and Novartis Venture Fund participated. M Ventures also contributed significantly. These same investors provided earlier funding. That capital supported the Investigational New Drug (IND) application. It also facilitated the initiation of the Phase 1 trial. This continued support reflects deep confidence. It signals belief in FoRx's lead candidate, FORX-428. It also validates the management team's progress. The company expressed gratitude for securing this syndicate's continued trust. The investment empowers critical clinical milestones.
FoRx's financing mirrors a broader trend. European biotech investment remains robust. Capital flows into novel cancer mechanisms. Other companies also secured substantial funding in 2025. Hedera Dx, another Swiss firm, raised €15 million. This expanded access to targeted cancer care. Highlight Therapeutics in Spain received €15 million. They advance immuno-oncology treatments. T-Therapeutics in the UK secured €27.5 million. They develop immune-based therapies. Larger, later-stage rounds also occurred. Adcytherix in France closed €105 million. This financed antibody-drug conjugates. Artios Pharma raised €99 million. This expanded its precision oncology pipeline.
Collectively, these disclosed rounds total roughly €306 million in 2025. This funding focuses on European oncology biotechs. FoRx's investment aligns with this pattern. It shows sustained interest in differentiated cancer biology. Targets range from DNA damage response pathways to immuno-oncology. Targeted delivery platforms also attract capital. This widespread investment highlights a dynamic sector. Innovation in cancer treatment continues at pace.
The potential impact of PARG inhibition is significant. It represents a promising therapeutic strategy in oncology. FoRx aims to reinforce FORX-428's best-in-class profile. The company seeks to make a substantial difference for patients. Those with resistant cancers often face limited options. FORX-428 could offer renewed hope. It targets a critical vulnerability in these tumors. The upcoming clinical data will be pivotal. It will inform future development pathways.
FoRx Therapeutics stands at a critical juncture. Its new funding accelerates a novel cancer therapy. FORX-428 holds immense promise. It offers a new weapon against advanced solid tumors. The biotech sector watches closely. Patients worldwide await breakthroughs. This investment drives progress. It moves science closer to a cure for resistant cancers.